With this morning's announcement of another FDA appeal denial regarding Duchenne muscular dystrophy agent Translarna, PTC Therapeutics also mentioned that FDA is still willing to consider the approval of this agent under the accelerated approval pathway, Citi analyst Joel Beatty told investors earlier in a research note. He views this as a "meaningful positive" for PTC, believing it supports that Translarna could still receive an FDA approval. Beatty adds that he and the Street are giving the company zero credit for U.S. sales. He sees the company as a Buy either way. PTC Therapeutics closed the trading day up 21c to $24.14.